The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Giant Cell Arteritis Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2029
Synopsis
The global Giant Cell Arteritis Therapeutic market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.
This report is a detailed and comprehensive analysis for global Giant Cell Arteritis Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Giant Cell Arteritis Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Giant Cell Arteritis Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Giant Cell Arteritis Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc and F. Hoffmann-La Roche Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Giant Cell Arteritis Therapeutic market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Prednisone
Methotrexate
Tocilizumab
Aspirin
Market segment by Application
Corticosteroids
Immunosuppressive Agents
Anticoagulants
Others
Market segment by players, this report covers
Sanofi
Kiniksa Pharmaceuticals, Ltd.
Regeneron
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Novartis AG
AbbVie, Inc.
Bristol-Myers Squibb Company
Abbott
Johnson & Johnson Services, Inc.
Johns Hopkins Hospital
Fortis Healthcare
American College of Rheumatology
Duke University Health System
Lahey Clinic Foundation
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Giant Cell Arteritis Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Giant Cell Arteritis Therapeutic, with revenue, gross margin and global market share of Giant Cell Arteritis Therapeutic from 2018 to 2023.
Chapter 3, the Giant Cell Arteritis Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Giant Cell Arteritis Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Giant Cell Arteritis Therapeutic.
Chapter 13, to describe Giant Cell Arteritis Therapeutic research findings and conclusion.
The global Giant Cell Arteritis Therapeutic market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.
This report is a detailed and comprehensive analysis for global Giant Cell Arteritis Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Giant Cell Arteritis Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Giant Cell Arteritis Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Giant Cell Arteritis Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc and F. Hoffmann-La Roche Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Giant Cell Arteritis Therapeutic market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Prednisone
Methotrexate
Tocilizumab
Aspirin
Market segment by Application
Corticosteroids
Immunosuppressive Agents
Anticoagulants
Others
Market segment by players, this report covers
Sanofi
Kiniksa Pharmaceuticals, Ltd.
Regeneron
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Novartis AG
AbbVie, Inc.
Bristol-Myers Squibb Company
Abbott
Johnson & Johnson Services, Inc.
Johns Hopkins Hospital
Fortis Healthcare
American College of Rheumatology
Duke University Health System
Lahey Clinic Foundation
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Giant Cell Arteritis Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Giant Cell Arteritis Therapeutic, with revenue, gross margin and global market share of Giant Cell Arteritis Therapeutic from 2018 to 2023.
Chapter 3, the Giant Cell Arteritis Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Giant Cell Arteritis Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Giant Cell Arteritis Therapeutic.
Chapter 13, to describe Giant Cell Arteritis Therapeutic research findings and conclusion.
Index1 Market Overview
1.1 Product Overview and Scope of Giant Cell Arteritis Therapeutic
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Giant Cell Arteritis Therapeutic by Type
1.3.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type in 2022
1.3.3 Prednisone
1.3.4 Methotrexate
1.3.5 Tocilizumab
1.3.6 Aspirin
1.4 Global Giant Cell Arteritis Therapeutic Market by Application
1.4.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Corticosteroids
1.4.3 Immunosuppressive Agents
1.4.4 Anticoagulants
1.4.5 Others
1.5 Global Giant Cell Arteritis Therapeutic Market Size & Forecast
1.6 Global Giant Cell Arteritis Therapeutic Market Size and Forecast by Region
1.6.1 Global Giant Cell Arteritis Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Giant Cell Arteritis Therapeutic Market Size by Region, (2018-2029)
1.6.3 North America Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.4 Europe Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.6 South America Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Giant Cell Arteritis Therapeutic Product and Solutions
2.1.4 Sanofi Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Kiniksa Pharmaceuticals, Ltd.
2.2.1 Kiniksa Pharmaceuticals, Ltd. Details
2.2.2 Kiniksa Pharmaceuticals, Ltd. Major Business
2.2.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
2.2.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments and Future Plans
2.3 Regeneron
2.3.1 Regeneron Details
2.3.2 Regeneron Major Business
2.3.3 Regeneron Giant Cell Arteritis Therapeutic Product and Solutions
2.3.4 Regeneron Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Regeneron Recent Developments and Future Plans
2.4 GlaxoSmithKline plc
2.4.1 GlaxoSmithKline plc Details
2.4.2 GlaxoSmithKline plc Major Business
2.4.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product and Solutions
2.4.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Giant Cell Arteritis Therapeutic Product and Solutions
2.6.4 Novartis AG Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis AG Recent Developments and Future Plans
2.7 AbbVie, Inc.
2.7.1 AbbVie, Inc. Details
2.7.2 AbbVie, Inc. Major Business
2.7.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
2.7.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 AbbVie, Inc. Recent Developments and Future Plans
2.8 Bristol-Myers Squibb Company
2.8.1 Bristol-Myers Squibb Company Details
2.8.2 Bristol-Myers Squibb Company Major Business
2.8.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product and Solutions
2.8.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.9 Abbott
2.9.1 Abbott Details
2.9.2 Abbott Major Business
2.9.3 Abbott Giant Cell Arteritis Therapeutic Product and Solutions
2.9.4 Abbott Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Abbott Recent Developments and Future Plans
2.10 Johnson & Johnson Services, Inc.
2.10.1 Johnson & Johnson Services, Inc. Details
2.10.2 Johnson & Johnson Services, Inc. Major Business
2.10.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
2.10.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Johnson & Johnson Services, Inc. Recent Developments and Future Plans
2.11 Johns Hopkins Hospital
2.11.1 Johns Hopkins Hospital Details
2.11.2 Johns Hopkins Hospital Major Business
2.11.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product and Solutions
2.11.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Johns Hopkins Hospital Recent Developments and Future Plans
2.12 Fortis Healthcare
2.12.1 Fortis Healthcare Details
2.12.2 Fortis Healthcare Major Business
2.12.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Product and Solutions
2.12.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Fortis Healthcare Recent Developments and Future Plans
2.13 American College of Rheumatology
2.13.1 American College of Rheumatology Details
2.13.2 American College of Rheumatology Major Business
2.13.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Product and Solutions
2.13.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 American College of Rheumatology Recent Developments and Future Plans
2.14 Duke University Health System
2.14.1 Duke University Health System Details
2.14.2 Duke University Health System Major Business
2.14.3 Duke University Health System Giant Cell Arteritis Therapeutic Product and Solutions
2.14.4 Duke University Health System Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Duke University Health System Recent Developments and Future Plans
2.15 Lahey Clinic Foundation
2.15.1 Lahey Clinic Foundation Details
2.15.2 Lahey Clinic Foundation Major Business
2.15.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product and Solutions
2.15.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Lahey Clinic Foundation Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Giant Cell Arteritis Therapeutic Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Giant Cell Arteritis Therapeutic by Company Revenue
3.2.2 Top 3 Giant Cell Arteritis Therapeutic Players Market Share in 2022
3.2.3 Top 6 Giant Cell Arteritis Therapeutic Players Market Share in 2022
3.3 Giant Cell Arteritis Therapeutic Market: Overall Company Footprint Analysis
3.3.1 Giant Cell Arteritis Therapeutic Market: Region Footprint
3.3.2 Giant Cell Arteritis Therapeutic Market: Company Product Type Footprint
3.3.3 Giant Cell Arteritis Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Giant Cell Arteritis Therapeutic Consumption Value and Market Share by Type (2018-2023)
4.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2023)
5.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Application (2024-2029)
6 North America
6.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
6.2 North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
6.3 North America Giant Cell Arteritis Therapeutic Market Size by Country
6.3.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
6.3.2 United States Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
6.3.3 Canada Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
6.3.4 Mexico Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
7.2 Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
7.3 Europe Giant Cell Arteritis Therapeutic Market Size by Country
7.3.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
7.3.2 Germany Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.3 France Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.5 Russia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.6 Italy Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size by Region
8.3.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2029)
8.3.2 China Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.3 Japan Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.4 South Korea Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.5 India Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.7 Australia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
9 South America
9.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
9.2 South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
9.3 South America Giant Cell Arteritis Therapeutic Market Size by Country
9.3.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
9.3.2 Brazil Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
9.3.3 Argentina Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Country
10.3.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
10.3.2 Turkey Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10.3.4 UAE Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Giant Cell Arteritis Therapeutic Market Drivers
11.2 Giant Cell Arteritis Therapeutic Market Restraints
11.3 Giant Cell Arteritis Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Giant Cell Arteritis Therapeutic Industry Chain
12.2 Giant Cell Arteritis Therapeutic Upstream Analysis
12.3 Giant Cell Arteritis Therapeutic Midstream Analysis
12.4 Giant Cell Arteritis Therapeutic Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
